Yesterday (March 18) PureTech Health plc announced the completion of the acquisition of its founded entity, Karuna Therapeutics, Inc., by Bristol Myers Squibb for a staggering $14 billion.
Healthcare technology company Koneska is extending its contribution to critical neuroscience research by collaborating with an academic partnership program.
The company will split into two separate entities, one will focus on the development of neuroscience therapies and the other will become a standalone CDMO.
The Bill and Melinda Gates Foundation grant, awarded to data management platform Flywheel, will support pediatric brain development in impoverished areas.
Amylgen and Neuron-Experts partner to create a comprehensive offering of in-vivo and in-vitro efficacy evaluation for compounds in neurodegenerative diseases.
After one year of collaborative work, Metrion and LifeArc agree to continue research on a joint project focused on neuroscience ion channel drug discovery for another year.
PPD adds clinical research unit with ‘strong’ recruiting track record to its portfolio, enabling studies on patient populations ‘more reflective’ of the products’ end-users.
Lundbeck announces the acquisition of Abide, which provides the former with access to an R&D platform, a Phase II drug candidate, and drug discovery site in California.
